GLOW 70MG

What Is GLOW 70mg?

GLOW 70mg is a custom-formulated lyophilised triple-peptide research blend developed exclusively by Arma Peptides, combining three of the most widely studied regenerative compounds into a single high-concentration vial. Each vial contains BPC-157 10mg, TB-500 10mg, and GHK-Cu 50mg — totalling 70mg of lyophilised powder at ≥99% purity across all three components. BPC-157 (CAS 137525-51-0, PubChem CID 9941957) is a synthetic 15-amino-acid gastric pentadecapeptide with MW 1,419.5 g/mol. TB-500 (CAS 885340-08-9, PubChem CID 62707662) is a synthetic fragment of Thymosin Beta-4 with MW 4,963.4 g/mol. GHK-Cu (CAS 49557-75-7) is a naturally occurring copper-binding tripeptide (Glycine-Histidine-Lysine complexed with Cu²⁺) with MW 340.38 g/mol, extensively documented in skin and wound biology research. All three components in GLOW 70mg are independently verified by HPLC and mass spectrometry — results available on our Certificate of Analysis page. For research use only.

Three-Pathway Research in One Vial

What makes GLOW 70mg distinct is the convergence of three non-overlapping biological mechanisms in a single formulation. BPC-157 acts primarily through VEGFR2-mediated angiogenesis, growth hormone receptor upregulation in fibroblasts, and nitric oxide pathway modulation — driving vascularisation and structural tissue repair. TB-500 sequesters G-actin via its LKKTET motif, regulating cytoskeletal dynamics to accelerate cell migration and differentiation at injury and remodelling sites. GHK-Cu operates at the gene expression level — activating over 4,000 human genes involved in tissue remodelling, stimulating collagen and elastin synthesis, upregulating metalloproteinases (MMPs) for matrix turnover, and exerting potent antioxidant and anti-inflammatory effects. Together in the GLOW 70mg blend, these three mechanisms address tissue repair, dermal regeneration, and extracellular matrix renewal simultaneously — making it a uniquely broad-spectrum research compound.

GHK-Cu Component — Research Profile

GHK-Cu is among the most extensively published peptides in skin and wound healing biology. Research published in PMC6073405 (Regenerative and Protective Actions of the GHK-Cu Peptide in Human Skin) demonstrates its capacity to stimulate collagen types I, III, and IV synthesis, increase elastin and glycosaminoglycan production, and reverse gene expression patterns associated with ageing skin. GHK-Cu also activates superoxide dismutase and other antioxidant enzymes, and has shown wound-contracting and anti-inflammatory effects across multiple in vitro and in vivo models. Its dominance in the GLOW 70mg formulation at 50mg reflects its role as the primary dermal and extracellular matrix modulator in this blend.

BPC-157 Component — Research Profile

BPC-157 contributes deep-tissue repair capability to the GLOW 70mg blend. Its published mechanisms include upregulation of EGR1 (early growth response protein 1) in fibroblasts, promotion of collagen type I deposition, acceleration of tendon-to-bone healing in animal models, and modulation of the NO-system for vascular protection. BPC-157’s chemical stability — notably its resistance to gastric acid and broad pH tolerance — makes it a robust component in multi-peptide formulations. Comprehensive mechanistic data is documented in PMC8228050.

TB-500 Component — Research Profile

TB-500 rounds out the GLOW 70mg triad by targeting cell motility and cytoskeletal reorganisation — the mechanisms that physically move repair cells to sites of damage. As the active fragment of Thymosin Beta-4, TB-500 promotes angiogenesis, reduces acute and chronic inflammation, and has shown cardioprotective and musculoskeletal repair activity in preclinical models. A current scoping review of TB-500’s tissue repair applications is available in Applied Sciences (2026).

Storage & Handling

Store GLOW 70mg lyophilised powder at −20°C, protected from light and moisture. Reconstitute using bacteriostatic water or sterile saline immediately prior to use. Once reconstituted, store at 4°C and use within 28 days. Do not refreeze reconstituted solution. Handle under sterile laboratory conditions. This compound is not approved for human or veterinary use.

Technical Specifications

Related Research Peptides

• BPC-157 & TB500 Blend 20mg — dual-peptide blend without GHK-Cu
• GHK-Cu 50mg — isolated copper peptide for skin and matrix research
• GHK-Cu Skin Glow 100mg — high-dose GHK-Cu for extended dermal studies
• BPC-157 10mg — isolated BPC-157 for single-peptide protocols
• TB-500 5mg — isolated TB-500 for Thymosin Beta-4 pathway research